Osteoporosis on systemic mastocytosis: case report
Authors:
Vaňuga Peter 1; Ságová Ivana 1; Kulich Michal 1; Vaňuga Anton 1,2
Authors‘ workplace:
Endokrinologické oddelenie, Národný endokrinologický a diabetologický ústav n. o. (NEDÚ), Ľubochňa
1; Alpha medical, s. r. o., Martin
2
Published in:
Clinical Osteology 2020; 25(2): 85-91
Category:
Overview
Mastocytóza je raritné ochorenie, ktoré je charakterizované abnormálnou proliferáciou mastocytov, so širokým spektrom klinických prejavov v dôsledku postihnutia rôznych tkanív a orgánov. Častou manifestáciou systémovej mastocytózy, najmä v dospelosti, je osteoporóza. Najčastejším miestom postihnutia je lumbálna chrbtica, v dôsledku väčšej straty trabekulárnej kosti v porovnaní s kortikálnou kosťou. Patomechanizmus vzniku osteoporózy pri mastocytóze je multifaktoriálny. K osteoporóze dochádza jednak v dôsledku neoplastickej infiltrácie kostnej drene mastocytmi, najmä však vplyvom uvoľnených mediátorov z mastocytu ako napr. histamínu, heparínu, prostaglandínov, cytokínov, ktoré zvyšujú aktivitu osteoklastov, a tým aj kostnú resorpciu. V liečbe osteoporózy pri mastocytóze sú indikované najmä bisfosfonáty, ďalšou alternatívou je denosumab. V našej kazuistike popisujeme prípad 33-ročnej pacientky s anamnézou urticaria pigmentosa, s ťažkou manifestnou osteoporózou s kompresívnymi fraktúrami torakálnej a lumbálnej chrbtice na podklade agresívnej formy systémovej mastocytózy.
Keywords:
osteoporosis – bisphosphonates – Bone resorption – denosumab – systemic mastocytosis
Sources
Krishnaswamy G, Ajitawi O, Chi DS.The human mast cell: an overview. Methods Mol Biol 2006; 315: 13–34. Dostupné z DOI: <http://dx.doi.org/10.1385/1–59259–967–2:013>.
Arock M, Valent P. Pathogenesis, classification and treatmentof mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3(4): 497–516. Dostupné z DOI: <http://dx.doi.org/10.1586/ehm.10.42>.
Martinásková K. Mastocytózy – komplexný pohľad na problematiku. Dermatol Prax 2011; 5(1): 7–12. Dostupné z WWW: Dostupné z DOI: <http://www.solen.sk/pdf/0bcb7ffa68647a6077fc3b844e58e64e.pdf>.
Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemias. Blood 2016; 127(20) :2391–2402. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2016–03–643544>.
Horny HP, Metcalfe DD, Bennet JM et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL et al. WHO clasification of tumours of haemopoetic and lymphoid tissues. 4th ed. WHO – Lyon International Agency for Research in Cancer2008: 54–63. ISBN 978–9283224310.
Pardanani A, Akin C, Valent P. Pathogenesis, clinical features and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006; 19(3): 595–615. Dostupné z DOI: <http://dx.doi.org/10.1016/j.beha.2005.07.010>.
Lazur J. Systémová mastocytóza – diagnostika a prospektívy liečby. Onkológia 2019; 14(6): 434–438. Dostupné z WWW: <http://www.solen.sk/pdf/85adfc9725b48edf153ca1368a90dfb5.pdf>.
Rossini M, Zanotti R, Viapiana O et al. Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin North Am 2014; 34(2): 383–396. Dostupné z DOI: <http://dx.doi.org/10.1016/j.iac.2014.01.011>.
Escribano L, Alvarez-Twose I, Sánchez-Muñoz L et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124(3): 514–521. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2009.05.003>.
Barete S, Assous N, de Gennes C et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010; 69(10): 1838–1841. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2009.124511>.
Rossini M, Zanotti R, Bonadonna P et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011; 49(4): 880–885. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2011.07.004>.
Hartmann K, Henz BM. Mastocytosis: recent advances in defining the disease. Br J Dermatol 2001; 144(4): 682–695. Dostupné z DOI: <http://dx.doi.org/10.1046/j.1365–2133.2001.04123.x>.
Rossini M, Zanotti R, Orsolini G et al. Prevalence, pathogenesis and treatment options for mastocytosis related osteoporosis. Osteroporos Int 2016; 27(8): 2411–2421. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–016–3539–1>.
Van Gysel D, Oranje AP. Mastocytosis. Eur J Pediat Dermatol 2008; 18(2): 101–104. Dostupné z WWW: <https://www.ejpd.com/journal/index.php/EJPD/article/view/516>.
Van der Veer E, van der Goot W, de Monchy JG et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012; 67(3): 431–438. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1398–9995.2011.02780.x>.
Brockow K, Akin C, Huber M et al. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005; 115(2): 216–223. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clim.2005.01.011>.
Chiappetta N, Gruber B .The role of mast cells in osteoporosis. Semin Arthritis Rheum 2006; 36(1):32–36. Dostupné z DOI: <http://dx.doi.org/10.1016/j.semarthrit.2006.03.004>.
Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008; 49(1): 7–19. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdermsci.2007.09.009>.
Biosse-Duplan M, Baroukh B, Dy M et al. Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 2009; 174(4): 1426–1434. Dostupné z DOI: <http://dx.doi.org/10.2353/ajpath.2009.080871>.
Chiappetta N, Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum 2006; 36(1): 32–36. Dostupné z DOI: <http://dx.doi.org/10.1016/j.semarthrit.2006.03.004>.
Rossini M, Viapiana O, Zanotti R et al. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis. Calcif Tissue Int 2015; 96(5):410–416. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223–015–9969–5>.
Rossini M, Adami S, Zanotti R et al. Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 2014; 133(3): 933–935. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2013.12.007>.
Genant HK, Wu CY, van Kuijk C et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8(9): 1137–1148. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.5650080915>.
Guillaume N, Desoutter J, Chandesris O et al. Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 2013; 126(1): 75–84. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2012.07.018>.
Seitz S, Barvencik F, Koehne T, Priemel M et al. Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 2013; 24(8): 2325–2334. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–013–2305-x>.
Rossini M, Zanotti R, Viapiana O et al. Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 2014; 127(11): 1127–1134. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2014.06.015>.
Rossini M, Adami G, Adami S et al. Safety issues and adverse reactions with osteoporosis management. Expert Opin Drug Saf 2016; 15(3): 321–332. Dostupné z DOI: <http://doi: 10.1517/14740338.2016.1136287>.
Orsolini G, Gavioli I, Tripi I et al. Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series. Calcif Tissue Int 2017; 100(6): 595–598. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223–017–0241-z>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology TraumatologyArticle was published in
Clinical Osteology
2020 Issue 2
Most read in this issue
- Bone turnover markers in osteoporosis: a common statement on their use of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. Purkyne (SMBD CzMA JEP) and the Czech Society of Clinical Biochemistry within the Czech Medical Association of J.E. Purkyne (CSCB CzMA JEP)
- Osteolytic deposits of the pelvis leading to the diagnosis of primary hyperparathyreosis: case report
- Osteoporosis on systemic mastocytosis: case report
- Definition of osteoporotic (fragility) fracture: a statement of the Society for Metabolic Bone Diseases within the Czech Medical Association of J.E. Purkyne (SMOS CzMa of JEP)